Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance

Nunzio Pomara, Lisa M. Willoughby, James C. Ritchie, John J. Sidtis, David J. Greenblatt, Charles Nemeroff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: There is evidence of more widespread use and abuse of benzodiazepines (BZPs) among elderly women. However, factors underlying this observation are poorly understood but could be related to more intense withdrawal reactions, which are a major risk factor for continued BZP use. We previously reported elevations in interdose morning plasma cortisol levels in healthy elderly individuals after chronic treatment with alprazolam, possibly consistent with increased hypothalamic-pituitary-adrenal (HPA) axis activity and drug withdrawal. In this study, we examined sex-related differences in this population. Method: Twenty-five cognitively intact healthy elderly (13 women and 12 men) participated in a parallel, double-blind, placebo-controlled study that included a group that received acute and chronic (3 weeks) treatment with alprazolam (0.5 mg b.i.d.). Results: Elderly women, but not men, experienced significant elevations in interdose morning plasma cortisol levels over 3 weeks of chronic treatment with alprazolam (0.5 mg b.i.d.) compared to placebo. In addition, higher morning plasma cortisol levels were significantly associated with better cognitive performance but not with higher plasma drug levels or greater degree of tolerance development to an acute alprazolam challenge. Conclusion: Elderly females experienced a greater interdose activation of the HPA axis during treatment with therapeutic doses of alprazolam than men, which could be related to drug withdrawal.

Original languageEnglish
Pages (from-to)414-419
Number of pages6
JournalPsychopharmacology
Volume182
Issue number3
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Alprazolam
Hydrocortisone
Benzodiazepines
Placebos
Pharmaceutical Preparations
Therapeutics
Sex Characteristics
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. / Pomara, Nunzio; Willoughby, Lisa M.; Ritchie, James C.; Sidtis, John J.; Greenblatt, David J.; Nemeroff, Charles.

In: Psychopharmacology, Vol. 182, No. 3, 01.11.2005, p. 414-419.

Research output: Contribution to journalArticle

Pomara, Nunzio ; Willoughby, Lisa M. ; Ritchie, James C. ; Sidtis, John J. ; Greenblatt, David J. ; Nemeroff, Charles. / Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. In: Psychopharmacology. 2005 ; Vol. 182, No. 3. pp. 414-419.
@article{1892cfe57c8b414d90abba074caa3c4c,
title = "Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance",
abstract = "Objective: There is evidence of more widespread use and abuse of benzodiazepines (BZPs) among elderly women. However, factors underlying this observation are poorly understood but could be related to more intense withdrawal reactions, which are a major risk factor for continued BZP use. We previously reported elevations in interdose morning plasma cortisol levels in healthy elderly individuals after chronic treatment with alprazolam, possibly consistent with increased hypothalamic-pituitary-adrenal (HPA) axis activity and drug withdrawal. In this study, we examined sex-related differences in this population. Method: Twenty-five cognitively intact healthy elderly (13 women and 12 men) participated in a parallel, double-blind, placebo-controlled study that included a group that received acute and chronic (3 weeks) treatment with alprazolam (0.5 mg b.i.d.). Results: Elderly women, but not men, experienced significant elevations in interdose morning plasma cortisol levels over 3 weeks of chronic treatment with alprazolam (0.5 mg b.i.d.) compared to placebo. In addition, higher morning plasma cortisol levels were significantly associated with better cognitive performance but not with higher plasma drug levels or greater degree of tolerance development to an acute alprazolam challenge. Conclusion: Elderly females experienced a greater interdose activation of the HPA axis during treatment with therapeutic doses of alprazolam than men, which could be related to drug withdrawal.",
author = "Nunzio Pomara and Willoughby, {Lisa M.} and Ritchie, {James C.} and Sidtis, {John J.} and Greenblatt, {David J.} and Charles Nemeroff",
year = "2005",
month = "11",
day = "1",
doi = "10.1007/s00213-005-0088-2",
language = "English",
volume = "182",
pages = "414--419",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance

AU - Pomara, Nunzio

AU - Willoughby, Lisa M.

AU - Ritchie, James C.

AU - Sidtis, John J.

AU - Greenblatt, David J.

AU - Nemeroff, Charles

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Objective: There is evidence of more widespread use and abuse of benzodiazepines (BZPs) among elderly women. However, factors underlying this observation are poorly understood but could be related to more intense withdrawal reactions, which are a major risk factor for continued BZP use. We previously reported elevations in interdose morning plasma cortisol levels in healthy elderly individuals after chronic treatment with alprazolam, possibly consistent with increased hypothalamic-pituitary-adrenal (HPA) axis activity and drug withdrawal. In this study, we examined sex-related differences in this population. Method: Twenty-five cognitively intact healthy elderly (13 women and 12 men) participated in a parallel, double-blind, placebo-controlled study that included a group that received acute and chronic (3 weeks) treatment with alprazolam (0.5 mg b.i.d.). Results: Elderly women, but not men, experienced significant elevations in interdose morning plasma cortisol levels over 3 weeks of chronic treatment with alprazolam (0.5 mg b.i.d.) compared to placebo. In addition, higher morning plasma cortisol levels were significantly associated with better cognitive performance but not with higher plasma drug levels or greater degree of tolerance development to an acute alprazolam challenge. Conclusion: Elderly females experienced a greater interdose activation of the HPA axis during treatment with therapeutic doses of alprazolam than men, which could be related to drug withdrawal.

AB - Objective: There is evidence of more widespread use and abuse of benzodiazepines (BZPs) among elderly women. However, factors underlying this observation are poorly understood but could be related to more intense withdrawal reactions, which are a major risk factor for continued BZP use. We previously reported elevations in interdose morning plasma cortisol levels in healthy elderly individuals after chronic treatment with alprazolam, possibly consistent with increased hypothalamic-pituitary-adrenal (HPA) axis activity and drug withdrawal. In this study, we examined sex-related differences in this population. Method: Twenty-five cognitively intact healthy elderly (13 women and 12 men) participated in a parallel, double-blind, placebo-controlled study that included a group that received acute and chronic (3 weeks) treatment with alprazolam (0.5 mg b.i.d.). Results: Elderly women, but not men, experienced significant elevations in interdose morning plasma cortisol levels over 3 weeks of chronic treatment with alprazolam (0.5 mg b.i.d.) compared to placebo. In addition, higher morning plasma cortisol levels were significantly associated with better cognitive performance but not with higher plasma drug levels or greater degree of tolerance development to an acute alprazolam challenge. Conclusion: Elderly females experienced a greater interdose activation of the HPA axis during treatment with therapeutic doses of alprazolam than men, which could be related to drug withdrawal.

UR - http://www.scopus.com/inward/record.url?scp=26844582076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844582076&partnerID=8YFLogxK

U2 - 10.1007/s00213-005-0088-2

DO - 10.1007/s00213-005-0088-2

M3 - Article

VL - 182

SP - 414

EP - 419

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -